Artificial intelligence: A transformative tool in precision oncology.
CT
MRI
PET
SPECT
artificial intelligence
immunotherapy
lactate dehydrogenase
oncology
radiomics
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
Artificial intelligence (AI) is revolutionizing society and healthcare, offering new possibilities for precision medicine. Immunotherapy in oncology (IO) has similarly transformed cancer treatment through novel mechanisms of therapeutic action, but has also led to atypical response patterns that challenge traditional methods for response evaluation. This editorial explores the role of AI in addressing these challenges through the development of new biomarkers for precise disease characterization, and in particular those built on imaging for the early response assessment of patients diagnosed with cancer and treated with IO. Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation.
Identifiants
pubmed: 39186000
pii: 28639
doi: 10.18632/oncotarget.28639
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM